Bone Study Shows ImpediMed's SOZO Measures Cancer Patients’ Bone Mineral Content

March 9, 2022

ImpediMed’s SOZO digital health platform achieved results comparable to dual x-ray absorptiometry in assessing bone mineral content in cancer patients, the company reported at the 39th Annual Miami Breast Cancer Conference, March 3-6.

SOZO is a noninvasive bioimpedance spectroscopy device that provides a snapshot of fluid status and tissue composition in less than 30 seconds.

The study demonstrated a strong correlation between skeletal muscle mass data collected using SOZO and bone mineral content (BMC) data collected using dual x-ray absorptiometry in healthy subjects, cancer patients during treatment and cancer patients after treatment.

Multiple studies have shown a strong a correlation between skeletal muscle mass and bone “suggesting that a SOZO reading can provide a simple, quick and reproducible estimate of BMC,” the company said.

View today's stories